...
首页> 外文期刊>Molecular cancer therapeutics >Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment.
【24h】

Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment.

机译:重组组织蛋白酶S前肽通过抑制肿瘤微环境中的组织蛋白酶L样蛋白酶来减弱细胞侵袭。

获取原文
获取原文并翻译 | 示例

摘要

Human cathepsin L along with cathepsin S, K, and V are collectively known as cathepsin L-like proteases due to their high homology. The overexpression and aberrant activity of each of these proteases has been implicated in tumorigenesis. These proteases contain propeptide domains that can potently inhibit both their cognate protease and other proteases within the cathepsin L-like subfamily. In this investigation, we have produced the cathepsin S propeptide recombinantly and have shown that it is a potent inhibitor of the peptidolytic, elastinolytic, and gelatinolytic activities of the cathepsin L-like proteases. In addition, we show that this peptide is capable of significantly attenuating tumor cell invasion in a panel of human cancer cell lines. Furthermore, fusion of an IgG Fc-domain to the COOH terminus of the propeptide resulted in a chimeric protein with significantly enhanced ability to block tumor cell invasion. This Fc fusion protein exhibited enhanced stability in cell-based assays in comparison with the unmodified propeptide species. This approach for the combined inhibition of the cathepsin L-like proteases may prove useful for the further study in cancer and other conditions where their aberrant activity has been implicated. Furthermore, this strategy for simultaneous inhibition of multiple cysteine cathepsins may represent the basis for novel therapeutics to attenuate tumorigenesis.
机译:由于组织蛋白酶S,K和V的高度同源性,因此它们共同被称为组织蛋白酶L样蛋白酶。这些蛋白酶中的每一种的过表达和异常活性都与肿瘤发生有关。这些蛋白酶包含前肽域,该前肽域可有效抑制组织蛋白酶L样亚家族内的同源蛋白酶和其他蛋白酶。在这项研究中,我们重组生产了组织蛋白酶S前肽,并显示它是组织蛋白酶L样蛋白酶的肽分解,弹性蛋白酶和明胶分解活性的有效抑制剂。另外,我们显示该肽能够显着减弱一组人类癌细胞系中的肿瘤细胞侵袭。此外,IgG Fc结构域与前肽的COOH末端的融合产生了嵌合蛋白,其具有显着增强的阻断肿瘤细胞侵袭的能力。与未经修饰的前肽种类相比,该Fc融合蛋白在基于细胞的测定中显示出增强的稳定性。联合抑制组织蛋白酶L样蛋白酶的这种方法可能被证明可用于癌症和其他涉及其异常活性的疾病的进一步研究。此外,这种同时抑制多种半胱氨酸组织蛋白酶的策略可能代表了减轻肿瘤发生的新疗法的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号